$600 EpiPen Gets a $20 Alternative in Virginia

September 22nd, 2016 | by Vandita at AnonHQ.com


In 2015, when Martin Shkreli (CEO of Turing Pharmaceuticals) hiked the price of Daraprim (a drug used in the treatment of HIV) from $13.50 per pill to $750 (5,000% more expensive than its original cost), Mark L. Baum (CEO of San Diego-based Imprimis Pharmaceuticals) developed a $1 alternative to the life saving drug (and still made profits).

In 2007, when Mylan Pharmaceuticals acquired EpiPen (an epinephrine auto-injector used in the treatment of life threatening allergies and bee-sting emergencies) and hiked the price from a little over $100 to $600 in 2016 (a 500% increase for a one-year, two-pack supply), Jeremy Counts (owner of Main Street Pharmacy in Blacksburg, Virginia) promptly challenged the greedy generic drug manufacturer with a $20 alternative.

 “I buy the epinephrine in bulk and I get a good price and then I take the syringes and I pre-load them with 2 doses for people, and after I pre-load them, they’re ready to go. There is absolutely zero difference as far as the actual medication being delivered. The only difference is they’ve got a fancy pen with a spring in it.”

The only major difference between Count’s pens and Mylan’s EpiPens is that his alternative lasts about three months in storage while EpiPen lasts a year or 18 months maximum.

Enter Mark L. Baum.

Disgusted at Mylan’s decision to gouge the patients (considering the main ingredient, epinephrine, costs only a few dollars without the auto-injector), Baum is developing a customizable and compoundable alternative to EpiPen for less than $100.

Meanwhile, Dr Douglas McMahon from the Allergy and Asthma Center of Eagan, Minnesota, has created a cheaper and more compact epinephrine-delivering device — dubbed the AllergyStop — which he intends to sell for about a tenth of the price of EpiPen. Dr Douglas has already started crowd funding a $50 version of the EpiPen on IndieGogo with a $200,000 goal to complete quality testing and gain FDA approval. He told CBS Minnesota:

“I’ve been working on this for many years. I actually have severe food allergies myself, so I’ve needed to carry an Epinephrine device for many years. Throughout that process I’ve realized the current device [EpiPen] is really big and cumbersome, to the point where I hardly ever carried it. By chance I came to realize how inexpensive the parts were, including the medicine, and I realized we can sell it to patients for a very reasonable cost.”

San Diego-based Adamis Pharmaceuticals is also working on a pre-filled syringe system for injecting epinephrine, an alternative that will cost at least 40% less than the current market price for a one-year, two-pack supply of EpiPen. The product is currently under review by the FDA, and the company expects to start selling it in 2017.

Massachusetts-based Windgap Medical is also trying to get FDA approval for Abiliject, an EpiPen alternative that will have a shelf life of several years, making it more cost-effective than EpiPen. Abiliject, a device that won’t degrade when exposed to light or extreme temperatures, is about the size of a Bic lighter — less than half the girth of an EpiPen — so Windgap’s co-founder and CEO Christopher Stepanian believes users will be more likely to carry it with them at all times.

Two other EpiPen alternatives — the credit card-shaped Adrenacard, which can be stocked in one’s wallet, and a generic auto-injecting system from Teva Pharmaceuticals — are also in the works and could be available to consumers as soon as 2017.

But how did Mylan Pharmaceuticals get away with a 500% price increase in the very first place? Because it has a monopoly, writes Forbes, one that is maintained by the federal government’s own regulatory scheme which allowed, in fact encouraged, a billion-dollar market to be cornered by one supplier.

by Vandita – Creative Commons license – AnonHQ.com

Kyle James Leehttps://www.theaegisalliance.com
Majority Owner of The AEGIS Alliance. I studied in college for Media Arts, Game Development. Talents include Writer/Article Writer, Graphic Design, Photoshop, Web Design and Development, Video Production, Social Media, and eCommerce.

The AEGIS Alliance accepts monetary contributions

Subscribe to Our Newsletter


indicates required

Choose Subscription Types

Related Articles